Acumen Pharmaceuticals, Inc. — FY2021 Form 10-K
Reporting period: Year ended December 31, 2021; filed March 28, 2022. Acumen is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue. Its lead and sole disclosed candidate, ACU193, is an antibody targeting soluble amyloid-beta oligomers for early Alzheimer’s disease.
Financial results and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $0 | $1.436 million, NIH grant |
| Research and development expense | $12.305 million | $7.997 million |
| General and administrative expense | $7.279 million | $1.351 million |
| Operating loss | $19.584 million | $7.912 million |
| Net loss | $100.606 million | $7.325 million |
| Net cash used in operating activities | $17.961 million | $7.450 million |
- FY2021 net loss included $81.157 million of noncash expense from increases in the fair value of preferred-stock tranche and warrant liabilities. The tranche closed and the warrant was exercised during 2021; both liabilities were settled or reclassified. The reported net loss therefore substantially exceeded operating cash use.
- At year-end, cash and cash equivalents were $122.162 million and marketable securities were $103.694 million, totaling about $225.9 million. Working capital was $193.5 million; total assets were $230.3 million and total liabilities were $5.1 million. No funded debt is presented in the balance sheet.
- Financing provided $200.466 million of cash, principally $168.6 million net proceeds from the July 2021 IPO and $30.0 million gross proceeds from the Series B closing. The company reported $40.473 million shares outstanding at year-end.
- Management expects existing cash and marketable securities to fund operating and capital needs at least through 2025, based on its current plan and assumptions. It expects losses and expenses to rise as clinical development and public-company operations expand, and anticipates needing additional funding over time.
- Margins are not meaningful because the company has no product sales. It has never been profitable and has an accumulated deficit of $127.6 million.
Material changes versus FY2020
- Operating expenses rose $10.236 million, reflecting clinical-trial initiation, higher personnel and research costs, and the transition to public-company operations.
- Grant revenue fell to zero after the NIH grant’s remaining $1.4 million was recognized in 2020; the filing also reports a $0.1 million write-off of an uncollected grant receivable in 2021.
- Net loss increased sharply, primarily because of the noncash fair-value charges described above. Operating cash use also increased, but remained far below reported net loss.
- The IPO and conversion of preferred stock to common stock materially changed the capital structure; all outstanding preferred shares converted in connection with the IPO.
Business outlook, risks and unusual items
- ACU193’s INTERCEPT-AD Phase 1 trial was underway in early Alzheimer’s patients and remained in the single-ascending-dose portion at the filing date. The planned trial includes about 62 participants and assesses safety, tolerability, pharmacokinetics and target engagement; cognitive measures are exploratory.
- COVID-19-related site activation and enrollment delays led Acumen to expand anticipated trial sites. Management expected topline data in the first half of 2023; a possible adaptive Phase 2/3 program and FDA discussion were contingent on Phase 1 results.
- Management’s proposed advantages for ACU193—including more than 500-fold selectivity for oligomers over monomers and a potentially lower risk of ARIA—are based on nonclinical findings and remain unproven in humans. The filing reports successful sentinel safety review of the first two dosed patients, not clinical efficacy results.
- Key risks include dependence on a single candidate, uncertain clinical and regulatory outcomes, patient-enrollment delays, reliance on contract manufacturers and research organizations, competition, intellectual-property protection, reimbursement and the need for further financing. The company has no commercial infrastructure.
- The FDA had previously placed the IND on clinical hold over potential off-target binding; the hold was removed in April 2021 after supplemental testing. Nonclinical monkey testing also reported anaphylactoid-type reactions at the highest dose, while the stated no-observed-adverse-effect level was 300 mg/kg per dose.
- Acumen reported that a material weakness in segregation of accounting duties identified in 2020 was remediated in the second half of 2021. Management assessed disclosure controls as effective at year-end; the filing did not include management’s internal-control assessment report or an auditor attestation, as permitted for a newly public company.
- The independent auditor gave an unqualified opinion on the financial statements. The company reported no material legal proceedings.
Most important facts for investors to verify
- Whether INTERCEPT-AD enrollment, safety, ARIA monitoring and target-engagement data support advancement—and whether reported timelines or trial design change.
- Whether the stated cash runway through 2025 remains realistic as trial scope, manufacturing needs and operating costs evolve.
- The noncash nature and accounting valuation assumptions behind the $81.2 million fair-value charge, and the effect of subsequent financing or dilution.
- Whether ACU193’s proposed selectivity and safety profile, especially reduced ARIA risk, are demonstrated in human data rather than inferred from nonclinical studies.
- Progress in remediating and maintaining financial-reporting controls, and the implications of the company’s public-company transition.